Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors
19. Mai 2021 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL
05. April 2021 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
Teneobio Announces FDA Clearance of IND for TNB-585 and Initiation of Phase I Clinical Studies for Metastatic Castrate Resistant Prostate Cancer
26. Januar 2021 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific...
Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma
07. Dezember 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported...
Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies
01. Oktober 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced today that their investigational new drug application (IND) for TNB-486, a bispecific...
Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics
08. Juni 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9...
Teneobio Licenses Oncology Multispecific Product to Janssen
30. September 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
29. April 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific...
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy
22. Mai 2017 08:00 ET
|
TeneoBio, Inc
MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of...